NCT00152191View on ClinicalTrials.gov

A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,300

Participants

Timeline

Start Date

October 31, 1996

Primary Completion Date

October 31, 2007

Study Completion Date

January 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

UFT (uracil, tegafur)

uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years

DRUG

cyclophosphamide, methotrexate, and fluorouracil

cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8

Trial Locations (1)

Unknown

National Cancer Center, 5-1-1, Tsukiji, Chuo-ku

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT00152191 - A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC) | Biotech Hunter | Biotech Hunter